AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows:
- oncology (36.8%);
- respiratory diseases (22.9%);
- cardiovascular, renal and metabolic diseases (18.6%);
- other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases.
Net sales are distributed geographically as follows: the United Kingdom (2%), Continental Europe (16.5%), Americas (38.3%) and Africa/Asia/Australia (43.2%).
Number of employees : 70 600 people.
2018 2019 Delta GBP (in Million) % GBP (in Million) % Oncology 4,521 27.3% 6,794 35.5% +50.28% Cardiovascular, Renal & Metabolism 5,032 30.4% 5,413 28.3% +7.57% Respiratory 3,683 22.2% 4,226 22.1% +14.74% Other Diseases 2,550 15.4% 2,039 10.7% -20.04% Externalisation Revenue 780.71 4.7% 641.98 3.4% -17.77%
2019 GBP (in Million) % United States 6,308 33% China 3,815 20% Japan 1,977 10.3% United Kingdom 1,428 7.5% Other Asia, Africa and Australasia 1,112 5.8% Other Continental Europe 1,012 5.3% Sweden 653.74 3.4% Other Americas 638.06 3.3% Germany 551.84 2.9% France 453.07 2.4%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,312,668,724
1,256,822,435
95.7% 0
0.0% 95.7%
Shareholders AstraZeneca PLC (GB0009895292) AstraZeneca PLC (US)
Name Equities % Investor AB (Investment Company) 51,587,810
3.93% BlackRock Investment Management (UK) Ltd. 42,170,900
3.21% Capital Research & Management Co. (World Investors) 41,526,368
3.16% Wellington Management Co. LLP 38,725,550
2.95% The Vanguard Group, Inc. 37,200,514
2.83% Norges Bank Investment Management 31,680,000
2.41% BlackRock Fund Advisors 24,452,643
1.86% BlackRock Advisors (UK) Ltd. 16,769,205
1.28% Fidelity Management & Research Co. LLC 15,972,842
1.22% SSgA Funds Management, Inc. 13,880,589
1.06%
Name Equities % Investor AB (Investment Company) 190,171,620
7.24% Wellington Management Co. LLP 52,093,683
1.98% PRIMECAP Management Co. 51,498,061
1.96% Fidelity Management & Research Co. LLC 42,939,426
1.64% Jennison Associates LLC 31,035,458
1.18% Capital Research & Management Co. (International Investors) 29,249,466
1.11% Fisher Asset Management LLC 17,342,680
0.66% T. Rowe Price Associates, Inc. (Investment Management) 15,650,130
0.60% Capital Research & Management Co. 14,965,800
0.57% Dodge & Cox 14,821,346
0.56%
Name Equities % Valuation
AstraZeneca Pharma India Limited (506820) 18,750,000 75.0% 1,185,919,688 USD Viela Bio, Inc. (VIE) 14,650,334 26.7% 526,972,514 USD ADC Therapeutics SA (ADCT) 3,811,215 4.97% 121,996,992 USD Innate Pharma (IPH) 7,485,500 9.48% 31,708,054 USD Circassia Group Plc (CIR) 71,081,217 17.9% 27,400,388 USD PhaseBio Pharmaceuticals, Inc. (PHAS) 3,004,554 10.2% 10,095,301 USD Entasis Therapeutics Holdings Inc. (ETTX) 2,164,855 6.10% 5,347,192 USD
-
- Main Market
- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
- Bloomberg Code :
AZN:LN
- Reuters Code :
AZN.L
- Datastream Code :
AZN
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire
Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site :
http://www.astrazeneca.com
AstraZeneca : Foreigners net sellers of Asian equities in 2020, despite fourth-quarter turnaround
Sector Pharmaceuticals - NEC
Connections : AstraZeneca PLC
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
